IP Library Granted Patent US 10,214,560
Granted Patent B2
US 10,214,560 · App. 15/933,800 · Granted Feb 26, 2019

Branched linker for protein drug conjugates

Inventors: Laurent Ducry (Sierre, CH); Bernhard Stump (Brig, CH); Heilam Wong (Guangzhou, CN); Jin She (Guangzhou, CN); Gayle Allway (Brig-Glis, CH)
Assignees: LONZA LTD; Lonza Guangzhou Nansha Ltd.
C07K5/06043A61K47/60A61K47/64A61K47/65A61K47/6809A61K47/6845
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,214,560
App. No.
15/933,800
Granted
Feb 26, 2019
Kind
B2
Abstract

The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.

Claims (11)

1. A compound of formula (VI):

wherein

AA 1 represents one alpha amino acid residue in which a carboxyl terminal thereof forms the shown amide bond to NH;

the alpha amino acid residue, AA 1 , having an alpha amino group denoted by structure (3);

R1 and R2 are identical or different and independently from each other selected from the group consisting of hydrogen and PGN;

PGN is a protecting group selected from the group consisting of Boc, Fmoc and benzyloxycarbonyl; and

AA 1 is a residue of an amino aid selected from the group consisting of alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, lysine, lysine with side chain amino group protected with acetyl or formyl groups, arginine, histidine, ornithine, ornithine with side chain amino group protected with acetyl or formyl groups, and citrulline.

2. A compound selected from the group consisting of the following compounds:

wherein R1 and R2 are identical or different and independently from each other selected from the group consisting of hydrogen and PGN; and

PGN is a protecting group selected from the group consisting of Boc, Fmoc and benzyloxycarbonyl.

3. A compound according to claim 2 , wherein the compound is selected from the group consisting of a compound of formula (6-3), a compound of formula (6-4), a compound of formula (6b-3), and a compound of formula (6b-4), as follows:

Assignments (1)
CHANGE OF NAME Recorded Feb 11, 2022
From: LONZA GUANGZHOU NANSHA LTD.
To: LONZA GUANGZHOU PHARMACEUTICAL LTD.
Reel/Frame 059082/0638 →
Priority Claims (3)
WO PCT/CN2011/071287 · Feb 25, 2011 · international
WO PCT/CN2011/077863 · Aug 1, 2011 · international
WO PCT/CN2011/081857 · Nov 7, 2011 · international
Continuity (2)
Division 14001237
Related Publication 20180258136A1 · Sep 13, 2018